Tarsus Pharmaceuticals, Inc.
TARS
Rang in Aktien
#4708
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aktienkurs
$68.50
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.21B
Veränderung (1 Tag)
-3.51%
Veränderung (1 Jahr)
-6.07%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategorie
Healthcare
EPS für Tarsus Pharmaceuticals, Inc. (TARS)
EPS zum June 2026 TTM: $-1.09
Laut den aktuellen Finanzberichten und dem Aktienkurs von Tarsus Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-1.09. Am Ende des Jahres 2023 betrug das EPS $-4.62 eine Steigerung gegenüber dem EPS von 2022, das $-2.52 betrug.
EPS-Verlauf von Tarsus Pharmaceuticals, Inc. von 2018 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
